Key Points
- Director Daniel Allen Gold sold 1,300,000 shares on Nov. 19 at an average price of $20.23 (about $26.3M), cutting his stake by 6.72% to 18,047,727 shares — the transaction was disclosed in an SEC filing.
- Roivant shares traded around $20.22 (market cap ~$13.81B) with a 52‑week range of $8.73–$21.35 and a negative P/E of -36.11, while 50‑ and 200‑day moving averages sit at $17.66 and $13.64 respectively.
- Analysts have a consensus rating of “Moderate Buy” with a consensus target of $22.56, and several firms (Goldman Sachs, Leerink, JPMorgan, HC Wainwright) have recently raised price targets or issued Buy/Overweight ratings.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) Director Daniel Allen Gold sold 1,300,000 shares of the business's stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00. Following the transaction, the director directly owned 18,047,727 shares in the company, valued at $365,105,517.21. This trade represents a 6.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Roivant Sciences Price Performance
NASDAQ:ROIV traded down $0.05 during trading hours on Friday, hitting $20.22. The company had a trading volume of 4,213,817 shares, compared to its average volume of 8,849,950. The company has a market capitalization of $13.81 billion, a PE ratio of -36.11 and a beta of 1.23. The stock has a 50-day moving average price of $17.66 and a 200 day moving average price of $13.64. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $21.35.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on ROIV shares. Wall Street Zen upgraded shares of Roivant Sciences from a "strong sell" rating to a "hold" rating in a research report on Sunday, November 16th. The Goldman Sachs Group upped their target price on Roivant Sciences from $20.00 to $24.00 and gave the stock a "buy" rating in a report on Thursday, September 18th. Leerink Partners restated an "outperform" rating and issued a $29.00 target price on shares of Roivant Sciences in a research note on Tuesday, November 11th. HC Wainwright lifted their price target on Roivant Sciences from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, September 18th. Finally, JPMorgan Chase & Co. upped their price target on Roivant Sciences from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $22.56.
Check Out Our Latest Analysis on ROIV
Institutional Trading of Roivant Sciences
Hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp increased its position in Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock valued at $25,000 after buying an additional 1,148 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after acquiring an additional 543 shares during the last quarter. CWM LLC grew its stake in shares of Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company's stock worth $34,000 after acquiring an additional 920 shares during the last quarter. Aster Capital Management DIFC Ltd increased its holdings in shares of Roivant Sciences by 75.8% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company's stock valued at $67,000 after acquiring an additional 1,900 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of Roivant Sciences by 94.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company's stock worth $46,000 after purchasing an additional 2,233 shares during the last quarter. 64.76% of the stock is owned by institutional investors.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
